11/02/2019 13:03:00

Lumere Closes Strategic Growth Capital Funding

CHICAGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Lumere, Inc., a leading provider of evidence-based analytics and services to reduce unwarranted and costly clinical variation, announced today the closure of a significant round of funding led by Heritage Group. The additional capital will be used to develop and further expand service offerings that enable evidence-led change at health systems nationwide.

“Today, health systems in more than 40 states rely on our proprietary data to make evidence-based decisions when evaluating and optimizing drug and device utilization. Our new services make it possible for physicians to leverage these insights when planning for their cases,” said Hani Elias, JD, MPH, Lumere co-founder and CEO.

“We invest in companies that are passionate about unraveling the complexities of U.S. healthcare and have demonstrated positive momentum. We have been exceedingly impressed with Lumere’s growth during the past three years and are eager to continue supporting their mission,” said Jesse Bland, Principal, Heritage Group, a growth equity firm backed by some of the nation’s leading healthcare companies. Heritage Group also led Lumere’s Series B financing in June 2016.

Combining the power of clinical evidence, data and subject matter expertise, Lumere has helped more than 650 healthcare facilities reduce unnecessary costs and clinical variation since 2012. Lumere’s service offerings have been developed as a result of customer need to bring evidence and analytics closer to the individual physician and have helped health systems save millions of dollars in supply and drug spend while improving overall patient outcomes.

“Healthcare organizations are under significant pressure to eliminate both unnecessary variation and cost,” said Scott Lancaster, MD, MBA, Clinical Director, Spectrum Health Ventures, a participating investor. “We leverage Lumere’s research and evidence insights to ensure we are using products with the strongest clinical evidence and best outcomes for our patients, all while lowering costs. We are committed to supporting Lumere in its quest to equip physicians with tools and insights to make the best decisions possible on every case they perform.”

About Lumere

Lumere is at the forefront of clinical decision making for drugs and devices, offering evidence-based solutions and services for all providers that improve care and reduce cost across the patient journey. For more information, visit lumere.com, find us on LinkedIn, follow @LumereHQ on Twitter and like us on Facebook.

For media inquiries, please contact:

Giana Gaughan

PR Manager, Lumere

ggaughan@lumere.com

lumerelogo.JPG

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Jul
 
Kan vi tåle en fredagsjoke? (og det er ikke Fingerprint Cards jeg tænker på :-) ) En blind mand går ..
30
11 Jul
VELO
Lånt fra skribent i FB gruppen “Veloxis Investor” “Hovedorganisationen for transplantationer i US..
26
12 Jul
 
Man hører det igen og igen. Donald Trump er ubegavet, dum, idiot - derudover racist, nazist - en opp..
25
10 Jul
GEN
I kurs 1500 var der også taget meget forskud på glæderne - og så har der været et par setbacks tilli..
18
12 Jul
PNDORA
Har lige været i Frankrig hvor jeg kiggede forbi en butik hvor jeg konstaterede at der var godt med ..
16
12 Jul
 
Han er den største psykopat, der nogen sinde har siddet ved magten, og han er DYBT ustabil og højst ..
15
11 Jul
DANSKE
Helt enig - desværre.   Danske Bank har i den grad været åben og informativ inden for rammerne af hv..
15
12 Jul
BAVA
Dejligt at se den er begyndt at stige - indenfor 2 1/2 mdr kommer der til at ske rigtig meget:   Ko..
12
12 Jul
 
Det eneste konkrete Tumpen har budt på er en ufinansieret skattereform. Det billigste trick i verden..
12
12 Jul
VELO
Den dér bemærkning kan du sgu' ikke være bekendt.  Synes lige du bør orientere dig bedre dig ved at ..
12

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SolarWinds New APAC Research Shows Insider Threats Rank as Top Cybersecurity Threat Concern
2
ROSEN, A TOP RANKED LAW FIRM, Reminds RCI Hospitality Holdings, Inc. Investors of July 22nd Deadline in Securities Class Action – RICK
3
Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
4
ROSEN, A TOP RANKED LAW FIRM, Reminds Community Health Systems, Inc. Investors of Important July 29th Deadline in the Securities Class Action– CYH
5
Black Creek Group Industrial Real Estate Investment Platform to be acquired by Prologis for $3.99 Billion

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 July 2019 09:59:13
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB2 - 2019-07-16 10:59:13 - 2019-07-16 09:59:13 - 1000 - Website: OKAY